Literature DB >> 17328581

Are population pharmacokinetic and/or pharmacodynamic models adequately evaluated? A survey of the literature from 2002 to 2004.

Karl Brendel1, Céline Dartois, Emmanuelle Comets, Annabelle Lemenuel-Diot, Christian Laveille, Brigitte Tranchand, Pascal Girard, Céline M Laffont, France Mentré.   

Abstract

Model evaluation is an important issue in population analyses. We aimed to perform a systematic review of all population pharmacokinetic and/or pharmacodynamic analyses published between 2002 and 2004 to survey the current methods used to evaluate models and to assess whether those models were adequately evaluated. We selected 324 articles in MEDLINE using defined key words and built a data abstraction form composed of a checklist of items to extract the relevant information from these articles with respect to model evaluation. In the data abstraction form, evaluation methods were divided into three subsections: basic internal methods (goodness-of-fit [GOF] plots, uncertainty in parameter estimates and model sensitivity), advanced internal methods (data splitting, resampling techniques and Monte Carlo simulations) and external model evaluation. Basic internal evaluation was the most frequently described method in the reports: 65% of the models involved GOF evaluation. Standard errors or confidence intervals were reported for 50% of fixed effects but only for 22% of random effects. Advanced internal methods were used in approximately 25% of models: data splitting was more often used than bootstrap and cross-validation; simulations were used in 6% of models to evaluate models by a visual predictive check or by a posterior predictive check. External evaluation was performed in only 7% of models. Using the subjective synthesis of model evaluation for each article, we judged the models to be adequately evaluated in 28% of pharmacokinetic models and 26% of pharmacodynamic models. Basic internal evaluation was preferred to more advanced methods, probably because the former is performed easily with most software. We also noticed that when the aim of modelling was predictive, advanced internal methods or more stringent methods were more often used.

Mesh:

Year:  2007        PMID: 17328581      PMCID: PMC2907410          DOI: 10.2165/00003088-200746030-00003

Source DB:  PubMed          Journal:  Clin Pharmacokinet        ISSN: 0312-5963            Impact factor:   6.447


  39 in total

1.  A population pharmacokinetic-pharmacodynamic analysis of repeated measures time-to-event pharmacodynamic responses: the antiemetic effect of ondansetron.

Authors:  E H Cox; C Veyrat-Follet; S L Beal; E Fuseau; S Kenkare; L B Sheiner
Journal:  J Pharmacokinet Biopharm       Date:  1999-12

Review 2.  Role of modelling and simulation in Phase I drug development.

Authors:  L Aarons; M O Karlsson; F Mentré; F Rombout; J L Steimer; A van Peer
Journal:  Eur J Pharm Sci       Date:  2001-05       Impact factor: 4.384

Review 3.  Pharmacokinetic/pharmacodynamic modeling in drug development.

Authors:  L B Sheiner; J L Steimer
Journal:  Annu Rev Pharmacol Toxicol       Date:  2000       Impact factor: 13.820

Review 4.  Optimizing the science of drug development: opportunities for better candidate selection and accelerated evaluation in humans.

Authors:  L J Lesko; M Rowland; C C Peck; T F Blaschke
Journal:  Pharm Res       Date:  2000-11       Impact factor: 4.200

5.  Pharmacokinetic modeling and simulations of interaction of amprenavir and ritonavir.

Authors:  Mark Sale; Brian M Sadler; Daniel S Stein
Journal:  Antimicrob Agents Chemother       Date:  2002-03       Impact factor: 5.191

6.  A pharmacokinetic simulation model for ivabradine in healthy volunteers.

Authors:  S B Duffull; S Chabaud; P Nony; C Laveille; P Girard; L Aarons
Journal:  Eur J Pharm Sci       Date:  2000       Impact factor: 4.384

7.  Semiphysiological model for the time course of leukocytes after varying schedules of 5-fluorouracil in rats.

Authors:  L E Friberg; A Freijs; M Sandström; M O Karlsson
Journal:  J Pharmacol Exp Ther       Date:  2000-11       Impact factor: 4.030

8.  The pharmacokinetics and cardiovascular effects of a single intravenous dose of protamine in normal volunteers.

Authors:  John Butterworth; Yonggu A Lin; Richard Prielipp; Judy Bennett; Robert James
Journal:  Anesth Analg       Date:  2002-03       Impact factor: 5.108

9.  Evaluating pharmacokinetic/pharmacodynamic models using the posterior predictive check.

Authors:  Y Yano; S L Beal; L B Sheiner
Journal:  J Pharmacokinet Pharmacodyn       Date:  2001-04       Impact factor: 2.745

10.  The influence of remifentanil on the dynamic relationship between sevoflurane and surrogate anesthetic effect measures derived from the EEG.

Authors:  Erik Olofsen; James W Sleigh; Albert Dahan
Journal:  Anesthesiology       Date:  2002-03       Impact factor: 7.892

View more
  60 in total

Review 1.  The relationship between drug clearance and body size: systematic review and meta-analysis of the literature published from 2000 to 2007.

Authors:  Sarah C McLeay; Glynn A Morrish; Carl M J Kirkpatrick; Bruce Green
Journal:  Clin Pharmacokinet       Date:  2012-05-01       Impact factor: 6.447

2.  Population pharmacokinetics and pharmacodynamics of bivalirudin in young healthy Chinese volunteers.

Authors:  Dong-mei Zhang; Kun Wang; Xia Zhao; Yun-fei Li; Qing-shan Zheng; Zi-ning Wang; Yi-min Cui
Journal:  Acta Pharmacol Sin       Date:  2012-06-04       Impact factor: 6.150

Review 3.  Overview of model-building strategies in population PK/PD analyses: 2002-2004 literature survey.

Authors:  C Dartois; K Brendel; E Comets; C M Laffont; C Laveille; B Tranchand; F Mentré; A Lemenuel-Diot; P Girard
Journal:  Br J Clin Pharmacol       Date:  2007-08-15       Impact factor: 4.335

4.  Commentary on Dartois et al.--model building in population PK-PD analyses. A 2002-2004 literature survey.

Authors:  Goonaseelan Pillai; Jean-Louis Steimer
Journal:  Br J Clin Pharmacol       Date:  2007-08-31       Impact factor: 4.335

5.  Reporting a population pharmacokinetic-pharmacodynamic study: a journal's perspective.

Authors:  Kris M Jamsen; Sarah C McLeay; Michael A Barras; Bruce Green
Journal:  Clin Pharmacokinet       Date:  2014-02       Impact factor: 6.447

6.  Pharmacokinetic design optimization in children and estimation of maturation parameters: example of cytochrome P450 3A4.

Authors:  Marion Bouillon-Pichault; Vincent Jullien; Caroline Bazzoli; Gérard Pons; Michel Tod
Journal:  J Pharmacokinet Pharmacodyn       Date:  2010-11-04       Impact factor: 2.745

7.  Evaluation of different tests based on observations for external model evaluation of population analyses.

Authors:  Karl Brendel; Emmanuelle Comets; Céline Laffont; France Mentré
Journal:  J Pharmacokinet Pharmacodyn       Date:  2009-12-23       Impact factor: 2.745

8.  Refinement of the population pharmacokinetic model for the monoclonal antibody matuzumab: external model evaluation and simulations.

Authors:  Katharina Kuester; Andreas Kovar; Christian Lüpfert; Brigitte Brockhaus; Charlotte Kloft
Journal:  Clin Pharmacokinet       Date:  2009       Impact factor: 6.447

9.  Population Pharmacokinetic Studies of Digoxin in Adult Patients: A Systematic Review.

Authors:  Mariam Abdel Jalil; Noura Abdullah; Mervat Alsous; Khawla Abu-Hammour
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2021-05       Impact factor: 2.441

10.  Cross-validation for nonlinear mixed effects models.

Authors:  Emily Colby; Eric Bair
Journal:  J Pharmacokinet Pharmacodyn       Date:  2013-03-27       Impact factor: 2.745

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.